Abstract
Background China lifted strict non-pharmacological interventions (NPIs) to prevent outbreaks of SARS-CoV-2 Omicron variants in December 2022. Relatively low levels of immunity and of vaccine booster coverage in the Chinese population raise concerns that future outbreaks will rapidly result in high rates of death and severe illness and will overwhelm health services.
Methods This was a compartmental, discrete-time population dynamic model. It compared projected deaths and hospitalisation under various scenarios, including booster vaccine coverage and strictness of NPIs.
Results We projected between 268,300 to 398,700 COVID-19 deaths, and peak numbers of hospitalised severe/critical cases between 3.2 to 6.4 per 10,000 population, before the outbreak wave recedes by February 2023. The COVID-19 deaths are reduced by 8% and 30%, respectively, under the weak and strict NPI scenarios, compared with the scenario without NPI measures. Early achievement of high coverage of three vaccine doses will further reduce COVID-19 deaths.
Conclusion We projected fewer COVID-19 deaths and hospitalisations than some other models have. Rapid expansion of booster vaccine coverage will only be effective if combined with strict NPIs and/or the high coverage of booster vaccination could be achieved early.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data relevant to the study are included in the article or in supplementary information. Computational R code is available from FS.
